{"id":"https://openalex.org/W7224765493","doi":"https://doi.org/10.1177/10781552261503888","title":"Administration-related reactions following first-dose subcutaneous daratumumab to inform implementation of a 30-minute observation period","display_name":"Administration-related reactions following first-dose subcutaneous daratumumab to inform implementation of a 30-minute observation period","publication_year":2026,"publication_date":"2026-10-29","ids":{"openalex":"https://openalex.org/W7224765493","doi":"https://doi.org/10.1177/10781552261503888","pmid":"https://pubmed.ncbi.nlm.nih.gov/42957977"},"language":"en","primary_location":{"id":"doi:10.1177/10781552261503888","doi":"https://doi.org/10.1177/10781552261503888","is_oa":false,"landing_page_url":"https://doi.org/10.1177/10781552261503888","pdf_url":null,"source":{"id":"https://openalex.org/S66425452","display_name":"Journal of Oncology Pharmacy Practice","issn_l":"1078-1552","issn":["1078-1552","1477-092X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Oncology Pharmacy Practice","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5137512410","display_name":"Jennifer Galvet","orcid":"https://orcid.org/0009-0007-2935-4514","observed_orcids":["https://orcid.org/0009-0007-2935-4514"]},"institutions":[{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer Galvet","raw_affiliation_strings":["Northwell Health Cancer Institute"],"raw_orcid":"https://orcid.org/0009-0007-2935-4514","affiliations":[{"raw_affiliation_string":"Northwell Health Cancer Institute","institution_ids":["https://openalex.org/I1302444339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152922166","display_name":"Sara S Kim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara S Kim","raw_affiliation_strings":["Northwell Health Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwell Health Cancer Institute","institution_ids":["https://openalex.org/I1302444339"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033263236","display_name":"Jessica Caro","orcid":"https://orcid.org/0000-0002-0792-8595","observed_orcids":["https://orcid.org/0000-0002-0792-8595"]},"institutions":[{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Caro","raw_affiliation_strings":["Northwell Health Cancer Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwell Health Cancer Institute","institution_ids":["https://openalex.org/I1302444339"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057983232","display_name":"David J. Chung","orcid":"https://orcid.org/0000-0003-0469-839X","observed_orcids":["https://orcid.org/0000-0003-0469-839X"]},"institutions":[{"id":"https://openalex.org/I1302444339","display_name":"Northwell Health","ror":"https://ror.org/02bxt4m23","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David J Chung","raw_affiliation_strings":["Northwell Health Cancer Institute"],"raw_orcid":"https://orcid.org/0000-0003-0469-839X","affiliations":[{"raw_affiliation_string":"Northwell Health Cancer Institute","institution_ids":["https://openalex.org/I1302444339"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5137512410"],"corresponding_institution_ids":["https://openalex.org/I1302444339"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.86046068,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"10781552261503888","last_page":"10781552261503888"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.5946999788284302,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.5946999788284302,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.1485999971628189,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0568000003695488,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.9079999923706055},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8769999742507935},{"id":"https://openalex.org/keywords/myeloma-treatment","display_name":"myeloma treatment","score":0.4659999907016754}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9442999958992004},{"id":"https://openalex.org/C2778300832","wikidata":"https://www.wikidata.org/wiki/Q1589604","display_name":"Premedication","level":2,"score":0.7752000093460083},{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.7245000004768372},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6208999752998352},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.5102999806404114},{"id":"https://openalex.org/C2781292560","wikidata":"https://www.wikidata.org/wiki/Q413486","display_name":"Diphenhydramine","level":3,"score":0.4586000144481659},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4505999982357025},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.365200012922287},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.35409998893737793},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3483999967575073},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.34630000591278076},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3386000096797943},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.3151000142097473},{"id":"https://openalex.org/C2780385302","wikidata":"https://www.wikidata.org/wiki/Q367158","display_name":"Protocol (science)","level":3,"score":0.2930999994277954},{"id":"https://openalex.org/C2987804222","wikidata":"https://www.wikidata.org/wiki/Q5376582","display_name":"End point","level":2,"score":0.2924000024795532},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2921000123023987},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2865999937057495},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2799000144004822},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.2782999873161316},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.265500009059906},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.26080000400543213},{"id":"https://openalex.org/C2780073493","wikidata":"https://www.wikidata.org/wiki/Q7523837","display_name":"Single Center","level":2,"score":0.2540000081062317},{"id":"https://openalex.org/C2776135927","wikidata":"https://www.wikidata.org/wiki/Q5242559","display_name":"Referral","level":2,"score":0.25189998745918274},{"id":"https://openalex.org/C2776904630","wikidata":"https://www.wikidata.org/wiki/Q356336","display_name":"Adept","level":3,"score":0.25110000371932983}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1177/10781552261503888","doi":"https://doi.org/10.1177/10781552261503888","is_oa":false,"landing_page_url":"https://doi.org/10.1177/10781552261503888","pdf_url":null,"source":{"id":"https://openalex.org/S66425452","display_name":"Journal of Oncology Pharmacy Practice","issn_l":"1078-1552","issn":["1078-1552","1477-092X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Oncology Pharmacy Practice","raw_type":"journal-article"},{"id":"pmid:42957977","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42957977","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W2400276917","https://openalex.org/W2512106959","https://openalex.org/W2560056218","https://openalex.org/W2947874495","https://openalex.org/W3012570191","https://openalex.org/W3032846824","https://openalex.org/W4220693451","https://openalex.org/W4220839813","https://openalex.org/W4220862006","https://openalex.org/W4319662066","https://openalex.org/W4321376026","https://openalex.org/W4367669532","https://openalex.org/W4388532912","https://openalex.org/W4392168464","https://openalex.org/W4400046620"],"related_works":["https://openalex.org/W7223145256","https://openalex.org/W3205620891","https://openalex.org/W7214019385","https://openalex.org/W3213734443","https://openalex.org/W3213848786","https://openalex.org/W4200280836","https://openalex.org/W7203825438","https://openalex.org/W3135519711","https://openalex.org/W4220839813","https://openalex.org/W3166145298"],"abstract_inverted_index":{"IntroductionSubcutaneous":[0],"daratumumab":[1,11,60,195],"has":[2],"lower":[3],"rates":[4],"of":[5,112,165,191,222],"administration-related":[6],"reactions":[7],"(ARRs)":[8],"than":[9],"intravenous":[10,151],"and":[12,26,42,70,90,95,149,155,168,215],"shorter":[13],"administration":[14,148],"times.":[15],"However,":[16],"the":[17,21,62,113,133,178,185,204],"optimal":[18],"monitoring":[19],"following":[20],"first":[22],"dose":[23],"remains":[24],"uncertain":[25],"varies":[27],"across":[28],"institutions.":[29],"This":[30],"medication":[31],"use":[32],"evaluation":[33],"assessed":[34],"first-dose":[35,58],"ARRs":[36,182,227],"under":[37],"a":[38,199],"2-h":[39],"observation":[40,101,115],"protocol":[41],"whether":[43],"available":[44],"findings":[45,219],"support":[46],"reduced":[47],"30-min":[48,114,192,223],"observation.MethodsThis":[49],"retrospective,":[50],"single-center":[51],"cohort":[52],"study":[53],"included":[54,82,160],"patients":[55,119,131,187],"who":[56],"received":[57],"subcutaneous":[59,194],"at":[61],"Zuckerberg":[63],"Cancer":[64],"Center":[65],"between":[66],"March":[67],"6,":[68],"2024,":[69],"July":[71],"31,":[72],"2025.":[73],"The":[74,171],"primary":[75,134],"endpoint":[76],"was":[77,196],"ARR":[78,139,143,201],"incidence.":[79],"Secondary":[80],"endpoints":[81],"time":[83],"to":[84,104,238],"onset,":[85],"CTCAE":[86],"version":[87],"6.0":[88],"severity,":[89],"management":[91],"interventions.":[92],"Premedication":[93,158],"adherence":[94],"potential":[96],"chair-time":[97],"savings":[98],"from":[99,102,121],"reducing":[100],"4":[103],"2":[105,209],"h":[106],"were":[107,126],"also":[108],"evaluated.":[109],"After":[110],"implementation":[111,190,221],"period,":[116],"26":[117,186],"additional":[118],"treated":[120],"April":[122],"through":[123],"June":[124],"2026":[125],"reviewed":[127],"for":[128],"ARRs.ResultsAmong":[129],"50":[130,166],"in":[132],"cohort,":[135],"one":[136],"experienced":[137],"an":[138],"(2%).":[140],"Grade":[141],"3":[142],"occurred":[144,183],"150":[145],"min":[146],"after":[147,176,189,229],"required":[150],"methylprednisolone,":[152],"diphenhydramine,":[153],"famotidine,":[154],"intramuscular":[156],"epinephrine.":[157],"deviations":[159],"diphenhydramine":[161],"25":[162],"mg":[163,167],"instead":[164],"omitted":[169],"montelukast.":[170],"patient":[172],"tolerated":[173],"subsequent":[174],"doses":[175],"receiving":[177],"complete":[179],"regimen.":[180],"No":[181],"among":[184],"evaluated":[188],"observation.ConclusionFirst-dose":[193],"associated":[197],"with":[198,203,212,225,233],"low":[200],"incidence,":[202],"only":[205],"reaction":[206],"occurring":[207],"beyond":[208],"h.":[210],"Together":[211],"published":[213],"evidence":[214],"institutional":[216],"experience,":[217],"these":[218],"supported":[220],"observation,":[224],"no":[226],"observed":[228],"implementation.":[230],"Larger":[231],"studies":[232],"longer":[234],"follow-up":[235],"are":[236],"warranted":[237],"further":[239],"assess":[240],"abbreviated":[241],"observation.":[242]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-31T00:00:00"}